Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes

0

The new integrated AID system is designed to connect the Abbott FreeStyle Libre® 3 sensors, the smallest in the world1 and the most precise2.3 continuous blood glucose monitoring sensor with readings every minute, CamDiab’s CamAPS FX mobile app, which connects to Ypsomed’s mylife™ YpsoPump® – create an intelligent, automated process to deliver insulin based on real-time glucose data. The smart, connected wearable solution is designed to continuously monitor a person’s glucose levels and automatically adjust and deliver the right amount of insulin at the right time, taking the guesswork out of insulin dosing.

“Our goal is to make diabetes care as easy as possible, which is why Abbott continues to expand its team of insulin delivery partners, digital coaching and technology leaders,” said Jared Watkins, senior vice president of Abbott’s Diabetes Care business. “We want to deliver new, advanced solutions that simplify and allow people to spend less time thinking about diabetes and more time living.”

“Poor blood sugar control leads to an increased risk of diabetes complications such as blindness and heart and kidney disease. We want to help people with diabetes better manage their blood sugar with cutting-edge technology. Our CamAPS FX, already approved in Europeis a highly adaptive algorithm that, when integrated with Abbott’s sensor, is designed to communicate with Ypsomed’s insulin pump to deliver the optimal insulin dose, easing the burden of managing a unpredictable condition day and night,” said Romain HovorkaDirector of CamDiab Ltd.

“We believe that society’s great challenges can only be met through partnerships, so we are proud to expand our partners and our connectivity to provide more freedom of choice in diabetes management. are combined, our mylife™ YpsoPump® with the FreeStyle Libre 3 system and the advanced hybrid adaptive closed-loop CamAPS FX application, we will be able to provide an additional AID system that is compact and lightweight, discreet and simple to use, mentioned Simon MichelCEO of Ypsomed.

The companies aim to complete development by the end of 2022 with commercial availability expected thereafter.

About Abbott
Abbott is a global healthcare leader helping people live more fully at all stages of life. Our portfolio of life-changing technologies spans the healthcare spectrum, with leading companies and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Join us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

About CamDiab
CamDiab Ltd is a digital health and personalized medicine company focused on the design, development and commercialization of its world-leading, interoperable, closed-loop application CamAPS FX. CamAPS FX is designed to use an adaptive, self-learning control algorithm, linked to a compatible continuous glucose monitoring device and compatible insulin pump, to autonomously calculate and direct insulin delivery to maintain tight glycemic control. Since its founding in 2019, its mission has been to help people with type 1 diabetes and their families live better lives. For more information visit www.camdiab.com or follow CamDiab Ltd and its products on Facebook, LinkedIn and Twitter @CamAPS_FX.

About Ypsomed
Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 35 years of experience. A leader in innovation and technology, it is a preferred partner of pharmaceutical and biotechnology companies for pens, auto-injectors, pump systems and liquid drug delivery software solutions. Ypsomed presents and markets its product portfolios under the mylife™ Diabetescare umbrella brands directly to patients or via pharmacies and hospitals as well as under YDS™ Ypsomed Delivery Systems in B2B transactions with pharmaceutical companies. The company is headquartered in Burgdorf, Swiss, and has a global network of production facilities, subsidiaries and distribution partners employing a workforce of approximately 1,900 employees worldwide. www.ypsomed.com

1 Among the sensors applied to the patient. Data on file, Abbott Diabetes Care.
2 FreeStyle Libre 3 User Manual.
3 Archived data. Abbott Diabetes Care, Inc. Comparison based on publicly available information.

SOURCEAbbott


Source link

Share.

Comments are closed.